Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 26th Preview)
-
Rare disease approvals and FDA stance
The FDA granted accelerated approval to Denali Therapeutics’ Avlayah (tividenofusp alfa) for Hunter syndrome, a decision that Denali frames as a return to a rare-disease surrogate-endpoint pathway after the agency’s recent string of tougher calls. Denali had faced scrutiny after prior setbacks, including a separate FDA rejection of Regenxbio’s related Hunter gene-therapy effort. Separately, the FDA cleared Corcept Therapeutics’ Lifyorli (relacorilant) in an accelerated timeline for ovarian cancer, adding another rare-disease- and oncology-relevant signal that the agency continues to move when evidence packages meet its threshold—even as it heightens review expectations in other cases. A parallel story emphasizes the broader impact on rare disease biotechs: FDA decisions now appear tightly linked to the quality and quantity of clinical evidence supporting both benefits and confirmatory pathways, with companies racing to align trial designs to FDA’s current evidentiary bar. Across the two approvals, market attention is likely to refocus on companies with accelerated-approval-ready endpoints and clear post-marketing study plans, especially where regulators previously rejected or delayed similar programs.
-
Big Pharma M&A to replenish oncology pipeline
Merck agreed to acquire Terns Pharmaceuticals in an all-cash $6.7 billion deal, aiming to bolster its oncology portfolio ahead of major patent expirations. Under the terms, Merck will pay $53 per share for Terns, with closing expected in the second quarter of 2026 subject to antitrust clearance and a majority tender. Terns’ lead candidate, TERN-701, is an oral BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 development for chronic myeloid leukemia. Merck highlighted early signals from the CARDINAL trial, positioning TERN-701 as differentiated by its allosteric mechanism and convenience as a potential challenger to existing CML standards. Analysts and company statements frame the acquisition as a response to the approaching “patent cliff” pressures for Merck’s cancer blockbusters, with the deal meant to create an additional hematology-oncology anchor beyond Keytruda. The acquisition also underscores how late-stage excitement in smaller oncology companies—particularly those with clean mechanistic differentiation—can translate quickly into strategic bids even when other markets remain selective.
-
Precision oncology regulatory reach in Japan
Japan’s Ministry of Health approved Haihe Biopharma and Taiho Oncology’s risovalisib for PIK3CA-mutant advanced or recurrent ovarian clear cell carcinoma, pairing it with companion diagnostic clearance for AmoyDx’s AmoyDx PIK3CA Mutation Detection Kit. The approval expands biomarker-defined treatment options in Japan and ties eligibility to tumor tissue real-time PCR testing for PIK3CA mutations. The kit will be used to identify patients eligible for risovalisib, marketed as Haizexin in Japan. Haihe’s deal structure—exclusive rights for Taiho in Japan—puts both drug and test squarely into the same regulatory pathway, a key operational consideration for commercialization and patient access. For biotech operators, the decision is another marker of how regulators are increasingly bundling precision therapeutics with companion diagnostics to streamline clinical adoption and reduce off-label use.
-
Precision medicine assays and EU diagnostics standards
Invivoscribe secured CE-IVDR certification for its IdentiClone Dx IGH assay, a test designed to detect immunoglobulin heavy chain (IGH) gene rearrangements in patients with suspected B-cell lymphoproliferative disorders. Under the EU’s IVDR framework, the assay is designated as Class C, meaning it is treated as a higher-risk diagnostic device. Invivoscribe said the kit is intended to be commercially available next month and uses peripheral blood samples with PCR plus electrophoresis readout and integrated interpretation software. The company described the certification as its first IVDR-certified test kit for clonal immunoglobulin gene rearrangements, strengthening its position in standardized Europe-wide adoption for diagnostics that guide patient management. This milestone matters for biotech and CDx developers because IVDR-compliant pathways can determine whether tests scale across EU markets and whether clinicians can consistently implement clonality monitoring.
-
Clinical trial updates in kidney disease drug development
Maze Therapeutics reported clinically meaningful Phase 2 top-line results for MZE829, an oral APOL1 inhibitor being tested in patients with broad APOL1-mediated kidney disease. The company said the drug delivered an average 35.6% reduction in urine protein levels measured by uACR at week 12 across 12 efficacy-evaluable participants. Maze plans to continue enrollment in its Horizon Phase 2 program and aims to meet with regulators to advance toward a pivotal trial. Results also showed stronger proteinuria reductions in FSGS subgroups and among patients without diabetes, which could shape how the company talks about efficacy breadth. Investors reacted negatively to the stock despite the positive readout, reflecting how high expectations for disease-modifying renal therapies can intensify volatility around early-stage endpoints. For the field, AMKD remains a sought-after precision indication with limited approved options, making differentiation around effect size and patient stratification critical for any competitor looking to take market share from Vertex’s approach.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.